Leveraging the wheat germ cell-free protein synthesis system to accelerate malaria vaccine development

Leveraging the wheat germ cell-free protein synthesis system to accelerate malaria vaccine development
复制标题

DOI:
10.1016/j.parint.2020.102224
复制
发表时间:
2021-02-01
影响因子:
1.9
通讯作者:
Takashima, Eizo
Takashima, Eizo
中科院分区:
医学3区
文献类型:
--
作者:
Kanoi, Bernard N.;Nagaoka, Hikaru;Takashima, Eizo

文献摘要

被引文献

相似文献

预防传染病的疫苗在公共卫生史上取得了巨大的成功。通过应用经典的疫苗设计策略,在开发针对病毒和细菌病原体的疫苗干预措施方面取得了重大突破。相比之下,疟疾疫苗的开发一直很缓慢。恶性疟原虫疟疾影响着数百万人,世界上近一半的人口处于感染的危险之中。几十年的专门研究告诉我们,开发一种有效的疫苗将是耗时、具有挑战性和昂贵的。然而,最近的进展,如优化强大的蛋白质合成平台,高通量免疫筛选方法,反向疫苗学,免疫原的结构设计,淋巴细胞库测序,以及人工智能的利用,已经更新了加速发现疟疾中的关键抗原的前景。深入了解疟疾免疫和分子机制的主要因素,可能会提供一个全面的方法来确定新的和高效的疫苗。在这篇综述中,我们讨论了利用小麦胚芽无细胞蛋白合成系统(WGCFS)来加速疟疾疫苗开发的新抗原发现的进展。
Vaccines against infectious diseases have had great successes in the history of public health. Major breakthroughs have occurred in the development of vaccine-based interventions against viral and bacterial pathogens through the application of classical vaccine design strategies. In contrast the development of a malaria vaccine has been slow. Plasmodium falciparum malaria affects millions of people with nearly half of the world population at risk of infection. Decades of dedicated research has taught us that developing an effective vaccine will be time consuming, challenging, and expensive. Nevertheless, recent advancements such as the optimization of robust protein synthesis platforms, high-throughput immunoscreening approaches, reverse vaccinology, structural design of immunogens, lymphocyte repertoire sequencing, and the utilization of artificial intelligence, have renewed the prospects of an accelerated discovery of the key antigens in malaria. A deeper understanding of the major factors underlying the immunological and molecular mechanisms of malaria might provide a comprehensive approach to identifying novel and highly efficacious vaccines. In this review we discuss progress in novel antigen discoveries that leverage on the wheat germ cell-free protein synthesis system (WGCFS) to accelerate malaria vaccine development.